Dyax Readies HAE Therapy Kalbitor For Launch; Awareness Precedes Approval
Executive Summary
Despite still awaiting FDA approval, Dyax is gearing up for the launch of its hereditary angioedema agent Kalbitor (ecallantide), focusing mainly on awareness and reimbursement issues